| The ubiquitin proteasome system—implications for cell cycle control and the targeted treatment of cancer F Bassermann, R Eichner, M Pagano Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1843 (1), 150-162, 2014 | 325 | 2014 |
| Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity R Eichner, M Heider, V Fernández-Sáiz, F van Bebber, AK Garz, ... Nature medicine 22 (7), 735-743, 2016 | 180 | 2016 |
| Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogénétique Hématologique study E Coyaud, S Struski, N Prade, J Familiades, R Eichner, C Quelen, ... Blood, The Journal of the American Society of Hematology 115 (15), 3089-3097, 2010 | 138 | 2010 |
| SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma V Fernández-Sáiz, BS Targosz, S Lemeer, R Eichner, C Langer, ... Nature cell biology 15 (1), 72-81, 2013 | 106 | 2013 |
| Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders C Kornauth, T Pemovska, GI Vladimer, G Bayer, M Bergmann, S Eder, ... Cancer discovery 12 (2), 372-387, 2022 | 89 | 2022 |
| The bicarbonate transporter SLC4A7 plays a key role in macrophage phagosome acidification V Sedlyarov, R Eichner, E Girardi, P Essletzbichler, U Goldmann, ... Cell host & microbe 23 (6), 766-774. e5, 2018 | 76 | 2018 |
| B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells MP Puissegur, R Eichner, C Quelen, E Coyaud, B Mari, K Lebrigand, ... Leukemia 26 (10), 2224-2232, 2012 | 70 | 2012 |
| The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma M Heider, R Eichner, J Stroh, V Morath, A Kuisl, J Zecha, J Lawatscheck, ... Molecular cell 81 (6), 1170-1186. e10, 2021 | 39 | 2021 |
| Detection of chemical engagement of solute carrier proteins by a cellular thermal shift assay M Hashimoto, E Girardi, R Eichner, G Superti-Furga ACS chemical biology 13 (6), 1480-1486, 2018 | 39 | 2018 |
| Cross talk networks of mammalian target of rapamycin signaling with the ubiquitin proteasome system and their clinical implications in multiple myeloma R Eichner, V Fernández-Sáiz, BS Targosz, F Bassermann International review of cell and molecular biology 343, 219-297, 2019 | 18 | 2019 |
| Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022; 12: 372–387. doi … C Kornauth, T Pemovska, GI Vladimer, G Bayer, M Bergmann, S Eder, ... DOI: https://doi. org/10.1158/2159-8290. CD-21-0538. PMID: https://www. ncbi …, 2023 | 14 | 2023 |
| Two cases of primary pulmonary angiosarcoma as a rare cause of lung haemorrhage R Eichner, S Schwendy, F Liebl, A Huber, R Langer Pathology-Journal of the RCPA 43 (4), 386-389, 2011 | 11 | 2011 |
| MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma J Stroh, A Seckinger, M Heider, M Rudelius, R Eichner, M Schick, ... Blood Advances 6 (2), 515-520, 2022 | 6 | 2022 |
| PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation R Eichner, M Essler, K Specht, K Wörtler, C Peschel, F Bassermann, ... Annals of hematology 93, 501-503, 2014 | 5 | 2014 |
| Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma R Eichner, K Wörtler, M Essler, M Rudelius, C Peschel, I Ringshausen, ... Annals of hematology 92, 277-278, 2013 | 2 | 2013 |
| MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma J Stroh, A Seckinger, M Heider, M Rudelius, R Eichner, M Schick, ... ONCOLOGY RESEARCH AND TREATMENT 44, 20-20, 2021 | 1 | 2021 |
| Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label … C Kornauth, T Pemovska, GI Vladimer, G Bayer, M Bergmann, S Eder, ... Blood 136, 2-4, 2020 | 1 | 2020 |
| MCT1 As Molecularly Validated Predictive Marker for Lenalidomide-Maintenance Therapy in Multiple Myeloma J Stroh, A Seckinger, M Heider, R Eichner, M Emde, H Salwender, ... Blood 134, 3187, 2019 | 1 | 2019 |
| Method for assessing the efficacy of IMiDs and composition or combination for use in treating IMiD sensitive diseases F Bassermann, R Eichner, V Fernandez-Saiz US Patent 10,398,688, 2019 | 1 | 2019 |
| Inhibiting MGAT1-mediated N-glycosylation reduces proliferation and adhesion of AML cells and increases affinities of anti-SLC3A2 directed immunotherapies P Smit, C Buehring-Uhle, C Nather, A Negraschus, U Goldmann, ... | | 2023 |
